# A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Study · id `cardio:ct-nct06664801` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06664801](<https://clinicaltrials.gov/study/NCT06664801>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06664801

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

## Technical summary

Registry record NCT06664801. Randomized; single masking; primary purpose treatment. Start 2024-11-14 (actual); primary completion 2025-11-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 164 participants (enrolled count; ClinicalTrials.gov record NCT06664801, source copy `cardio:ctgov-nct06664801-2025-12-05`, retrieved 2026-10-31)
- Started: 2024-11-14 (actual) (ClinicalTrials.gov record NCT06664801, source copy `cardio:ctgov-nct06664801-2025-12-05`, retrieved 2026-10-31)
- Primary completion: 2025-11-20 (actual) (ClinicalTrials.gov record NCT06664801, source copy `cardio:ctgov-nct06664801-2025-12-05`, retrieved 2026-10-31)
- Completion: 2025-11-20 (actual) (ClinicalTrials.gov record NCT06664801, source copy `cardio:ctgov-nct06664801-2025-12-05`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Canada; China; Colombia; Czechia; France; Germany; Hungary; Israel; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Taiwan; Thailand; United Kingdom (ClinicalTrials.gov record NCT06664801, source copy `cardio:ctgov-nct06664801-2025-12-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06664801-2025-12-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
- Acronym: LIGHTRAY
- Condition: Pulmonary Arterial Hypertension
- Intervention (Biological): Sotatercept
- Intervention (Biological): Background PAH Therapy
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 053dc07485676b74a63d78a701a350e15ecc445e1800a9ab66e2875f3e32ad99
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
